|
KMID : 0988920230210010043
|
|
Intestinal Research
2023 Volume.21 No. 1 p.43 ~ p.60
|
|
|
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
|
|
Koh Seong-Joon
Hong Sung-Noh
Park Soo-Kyung
Ye Byong-Duk
Kim Kyeong-Ok
Shin Jeong-Eun
Yoon Yong-Sik
Lee Hong-Sub
Jung Sung-Hoon
Choi Mi-Young
Na Soo-Young
Choi Chang-Hwan
Kim Joo-Sung
|
|
|
Abstract
|
|
|
|
Crohn’s disease (CD) is a relapsing and progressive condition characterized by diarrhea, abdominal pain, weight loss, and hematochezia that results in serious complications such as perforations, fistulas, and abscesses. Various medications, interventions, and surgical treatments have been used to treat CD. The Korean guidelines for CD management were distributed in 2012 and revised in 2017 by the Inflammatory Bowel Disease (IBD) Research Group of the Korean Association for the Study of Intestinal Diseases. Substantial progress in mucosal immunologic research has elucidated the pathophysiology of IBD, leading to development of biological agents for treatment of CD. The first developed biologic agent, tumor necrosis factor-α agents, were shown to be efficacious in CD, heralding a new era in management of CD. Subsequently, vedolizumab, a monoclonal antibody against integrin α4β7, and ustekinumab, a human monoclonal antibody that inhibits the common p40 subunit of interleukin-12 and interleukin-23, were both approved for clinical use and are efficacious and safe for both induction and maintenance of remission in moderate-to-severe CD patients. Moreover, a recent study showed the non-inferiority of CT-P13, an infliximab biosimilar, compared with infliximab in CD patients. The third Korean guidelines for CD management provide updated information regarding treatment of moderate-to-severe CD patients with biologic agents.
|
|
|
KEYWORD
|
|
|
Crohn disease, Guideline, Biologics, Biosimilars
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|